Notably, in the tumors of colon cancer patients grouped into high-GSK3α based on the best cutoff (Fig. 1B), the expression differences of GSK3α between tumors and DNTs were much more significant (Fig. 1C), although some stages were no longer significant after TNM staging, probably due to the limited number of samples. This evidence concerns the gene GSK3A and malignant colon neoplasm.